Moreover, the 36-month beta value for IGC is 1.72. Analysts have varying opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for IGC is 59.49M and currently, short sellers hold a 1.58% of that float. On April 15, 2024, IGC’s average trading volume was 786.05K shares.
IGC) stock’s latest price update
IGC Pharma Inc (AMEX: IGC)’s stock price has dropped by -16.96 in relation to previous closing price of 0.53. Nevertheless, the company has seen a loss of -32.24% in its stock price over the last five trading days. Accesswire reported 2023-04-18 that POTOMAC, MD / ACCESSWIRE / April 18, 2023 / IGC Pharma, Inc. (NYSE American:IGC) today announced that it will be presenting at the Planet MicroCap Showcase: VEGAS 2023 on Wednesday, April 26, 2023, at 4:30 PM (Local Time -PDT). Ram Mukunda, Chief Executive Officer, and Claudia Grimaldi, Principal Financial Officer, will be hosting the presentation and answering questions at the conclusion.
IGC’s Market Performance
IGC Pharma Inc (IGC) has seen a -32.24% fall in stock performance for the week, with a 32.16% gain in the past month and a 63.24% surge in the past quarter. The volatility ratio for the week is 16.68%, and the volatility levels for the past 30 days are at 19.30% for IGC. The simple moving average for the past 20 days is -5.27% for IGC’s stock, with a 30.44% simple moving average for the past 200 days.
IGC Trading at 18.08% from the 50-Day Moving Average
After a stumble in the market that brought IGC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -51.63% of loss for the given period.
Volatility was left at 19.30%, however, over the last 30 days, the volatility rate increased by 16.68%, as shares surge +30.83% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +51.76% upper at present.
During the last 5 trading sessions, IGC fell by -32.24%, which changed the moving average for the period of 200-days by +41.92% in comparison to the 20-day moving average, which settled at $0.4698. In addition, IGC Pharma Inc saw 57.12% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for IGC
Current profitability levels for the company are sitting at:
- -9.59 for the present operating margin
- 0.4 for the gross margin
The net margin for IGC Pharma Inc stands at -11.62. The total capital return value is set at -1.25. Equity return is now at value -103.36, with -90.30 for asset returns.
Based on IGC Pharma Inc (IGC), the company’s capital structure generated 0.03 points at debt to capital in total, while cash flow to debt ratio is standing at -23.36. The debt to equity ratio resting at 0.03. The interest coverage ratio of the stock is 1296.33.
Currently, EBITDA for the company is -10.91 million with net debt to EBITDA at 0.09. When we switch over and look at the enterprise to sales, we see a ratio of 23.26. The receivables turnover for the company is 13.22for trailing twelve months and the total asset turnover is 0.11. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.85.
Conclusion
To wrap up, the performance of IGC Pharma Inc (IGC) has been better in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
